A life science venture capital firm with offices in Western Europe and USA is investing from its third fund that typically makes equity investment into early-stage life science companies. The typical investment size ranges from €10 million-15 million. The third fund is looking to make 10 investments.
The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications and is most interested in product-focused companies at pre-clinical / clinical stages of development.
The firm primarily invests in private companies with experienced management teams, but has the ability to also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC With USA & Europe Offices Invests Up to €15M in Therapeutics and Medical Device Companies, Open to All Types of Technologies and Indications
2 MarHot Investor Mandate: USA-Based Venture Firm Seeks Investment Opportunities in Digital Health and Data-Driven Medical Devices, Primarily in North America
2 MarA newly established venture capital firm is seeking to invest in Seed to Series A companies. The firm expects to make most of their investments in North America, but has a global outlook and has evaluated opportunities from other geographies.
Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.
The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm Backed by a Family Trust Invests in All Life Science Technologies Related to Cardiovascular and Neurovascular Disease Globally
2 MarA philanthropic venture firm was established by a family trust to accelerate the development of promising technologies for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments. This US-based firm makes 4-5 investments each year of approximately $1-2 million into privately-held companies worldwide at both the seed and Series A stages. The firm operates under an evergreen structure and has made 49 investments to date.
While the firm is focused on cardiovascular, neurovascular and metabolic diseases (e.g., diabetes, dyslipidemia and obesity), The firm invests across all technology sectors including biotech, medtech, diagnostics, and regenerative medicine. The firm looks to invest in companies where its investment will help move the company to a value inflection point necessary for the next and larger financing round.
The firm invests in technologies that have the potential for a clear impact on patient therapy and/or standard of care, an adequate level of IP protection, well-defined use of proceeds with quantifiable and achievable milestones, and a clear understanding of the next round of fundraising needs including size and likely sources.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Asia-Based Investment Firm With $1B+ AUM Invests Around $5M and More Into Early Clinical Stage Projects, With Strong Interests in Therapeutics and Digital Therapeutics
2 MarAn investment firm headquartered in Asia manages over $1.2B AUM and makes initial investments generally around $5M, but has the capacity to invest much higher amounts depending on the opportunity and fit. While the firm’s focus is on more developed companies, the firm is actively seeking early-stage opportunities with strong global potential, and is open to considering those outside of their headquarters.
Within life sciences, the firm’s main focus is in therapeutics and digital therapeutics, but the firm is also interested in medical devices, diagnostics, and digital health/healthcare IT. The firm looks at all modalities and indications. When considering therapeutics companies, the firm prefers to invest in early clinical stage projects and tend to avoid investing in pre-clinical ones.
The firm has no specific company or management team requirements. The firm can act as either a lead or co-investor, and will seek board representation in companies they fund as a lead investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
The Art of Raising Money for a Life Sciences Company
23 FebBy Yang (Kenny) Zhou, Vice President of Marketing, LSN
Some of the biggest challenges executives of early-stage life sciences companies face is securing financing and forging their first licensing deals. Though they may possess deep scientific knowledge, finding the right investors and partners, and telling their story in a compelling way may require skills they have not yet developed. Life Science Nation works with entrepreneurs to tell their stories, identify potential investors and partners, and connect with them. Daniel Levine of Levine Media Group interviews Dennis Ford, founder and CEO of Life Science Nation, for BigBio Communications about the journey and challenges life sciences entrepreneurs make when they set out to raise money, what investors care about, and what steps they can take to best ensure their success. Listen here:
Life Science Nation & Brisbane Economic Development Agency (BEDA) Equals RESI Success
23 Feb Miriam Kent |
Interview with Miriam Kent, General Manager, Business Growth, Trade and Talent, Brisbane Economic Development Agency (BEDA)
By Caitlin Dolegowski, Marketing Manager, LSN |
 Caitlin Dolegowski |
Life Science Nation (LSN) worked with the Brisbane Economic Development Agency and their MedTech Accelerator cohort in a hybrid Entrepreneurial Education program that culminated at RESI JPM San Francisco. We talked with Miriam Kent, General Manager, Business Growth, Trade and Talent at BEDA to learn more about their take-aways from the education course and RESI conference and hear what is next for the MedTech innovation coming from Brisbane.
Caitlin Dolegowski (CD): Introduce us to Brisbane Economic Development Agency (BEDA) and discuss your focus in the life science industry and how the MedTech Accelerator cohort came to be?
Miriam Kent: General Manager, Business Growth, Trade and Talent at Brisbane Economic Development Agency: As Brisbane’s champion, BEDA works to enhance and promote the city’s reputation globally, drive visitation, and attract investment and talent in key growth industries.
We support domestic and international investors with full market entry and expansion strategies, while supporting local businesses to scale globally and grow through our accelerator programs.
BEDA’s MedTech Initiative is designed to elevate our exceptional local talent, to attract international investment, and fast-track life-saving medical products to the market.
Brisbane has a strong track-record for innovation thanks to our world-class research institutes and universities. We’re supporting the next generation of companies to stand out in a globally competitive market, to foster fresh developments and discoveries.
CD: BEDA brought a MedTech Accelerator cohort to work with Life Science Nation (LSN) in a hybrid (virtual and in person) educational program and wrapping the program at RESI JPM San Francisco, can you tell us about the startups that attended?
MK: A rapid test for sepsis, a bionic voice box, and an inhaler for anaphylaxis are just some of the life-changing healthcare innovations produced by the Brisbane cohort. We were extremely proud to see two Brisbane companies take out gold and bronze in the Innovator’s Pitch Challenge.
Field Orthopaedics impressed the panel of seasoned investors and industry experts to secure the top prize for their innovative surgical screws and nails for treating complex fractures.
Meanwhile, Max Kelsen, claimed bronze with its machine learning solutions that are transforming the way scientists store, analyse and work with data to fast-track vital research.
Leading Brisbane MedTech companies – Clinials, De Motu Cordis, Laronix, Microbio and Midnight Health were also awarded finalist seats and were successful in attracting global investor and partner interest.
CD: Congrats to the BEDA cohort who did very well in the Innovator’s Pitch Challenge at RESI JPM San Francisco, taking 1st and 3rd place! What aspects of the LSN educational program were most useful to help get the companies ready for JPM Week and pitching at RESI?
MK: While these businesses are experts in their fields, knowing how to pitch their idea and who to pitch to on a global stage can be a challenge for some early-stage ventures looking to secure investment. With the support of Life Science Nation, our cohort members have been able to create strategies and connections to advance their global fundraising campaigns in a pivotal international market.
Throughout the program, the cohort has also benefited from mentorship from peak bodies like Life Sciences QLD, industry leaders like Vaxxas and ASX-listed Microba, as well as advice from local investors and venture capital groups.
CD: The educational program also featured executives from leading MedTech firms such as Stryker and Philips; how do you think their contributions shaped the success of the cohort at RESI JPM?
MK: Insights shared by global leaders like Stryker provide invaluable context and underline the importance of a refined and strategic funding campaign.
Stryker’s recent investment in Brisbane’s Herston Quarter health precinct will help drive medical technology, innovation, and collaboration to improve patient outcomes and solidify our city’s capability and reputation as a global science and research leader.
CD: Did the mix of virtual content over several months and in-person tutoring at the start of the JPM Week work well?
MK: The mix of virtual and in-person content ensures we can deliver an intensive, comprehensive learning experience, in a convenient way for leaders with busy schedules.
It is exciting to see the discussion and collaborations across continents.
CD: What is next for BEDA’s MedTech Accelerator cohort?
MK: The feedback we’ve received has been hugely positive and we look forward to working with a new cohort for year two of our MedTech Accelerator in 2023.
The outstanding success of our local start-ups, in a competitive global market, is a testament to the quality of the research and development that’s happening here in Brisbane.
We’d like to thank Life Science Nation for partnering with us to support this vital industry.
Introducing Digital RESI March Panelists
23 FebBy Momo Yamamoto, Investor Research Analyst, LSN
Get ready as Digital RESI March is approaching within weeks! Life Science Nation (LSN) is excited to announce that our upcoming Digital RESI March, a fully virtual conference, will have 6 investor panels, giving you the latest insights on various early-stage life science industries. Panel topics include: Seed Funds, Impact Investors, Early-Stage Therapeutics, Aging at Home, and Health System Partners.
Life Science Nation’s upcoming 3-day RESI Conference will give you the chance to join robust discussions with seasoned investors. The curated panels are here to provide new entrepreneurs with advice and conversation on how to attract investors, reach fundraising goals, and make meaningful partnerships. The LSN team has recruited over 20 panelists from a wide range of sectors from traditional VC, corporate VC to foundations, strategics, angel groups, and big pharma. Note our Ealy Stage Therapeutics and Health System Partners panels as we brought them back to RESI March. As the 3-day conference will be fully virtual, take advantage of tuning in from the comfort of anywhere you are around the world!
Join the discussion with the panelists below for the latest scoop:
 |
 |
 |
| Joshua Barney Member Barrington Angels |
Caleb Bell Venture Partner Corundum Systems Biology |
Gaye Bok Partner Artificial Intelligence and Digital Innovation Fund (AIDIF) |
 |
 |
 |
| Steve Curtis Director, New Ventures BrightEdge |
Adam Hunke Principal Banner Venture Group |
Brenda Irwin Managing Partner & Co-Founder Relentless Venture Fund |
 |
 |
 |
| Rick Jones Partner BioAdvance |
Megan Krench Director of Investments Sanofi Ventures |
Yury Kukushkin Managing Director JDRF T1D Fund |
 |
 |
 |
| James Mayer Senior Manager, Investment & Venture Services Centre for Aging + Brain Health Innovation (CABHI) |
Brian Meshkin Managing Partner Profound Ventures |
Ravi Mistry Investor, Individual Angel 3iPartners |
 |
 |
 |
| Joseph Mocanu Managing Partner Verge Health Tech Fund |
John Perez Managing Director Ballad Health |
Martin Pfister Senior Investment Manager: Life Sciences High-Tech Gründerfonds |
 |
 |
 |
| Jack Rack Gomer Principal MultiCare Capital Partners |
Krish Ramadurai Partner Harmonix Fund |
Brock Reeve CEO and Co-Founder Eos BioInnovation |
 |
 |
 |
| Nadav Shimoni Head of Digital Health Arkin Holdings Ltd |
Yaniv Sneor Founding Member Mid Atlantic Bio Angels |
Mayank Taneja Director of Venture Investments OSF Healthcare Ventures |
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 